TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15287163

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different regression models
Number of subjects: 0
Study: 11142927

Group type: EXPERIMENTAL
Intervention: Formica rufa D6 (1 ml) + autologous blood (0.5 ml)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (1.5 ml NaCl intramuscular)
Number of subjects: 104
Study: 8678737

Group type: COMPARATOR
Intervention: Classical transplantation (gr. I, n = 40)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Anatomical transplantation (gr. II, n = 41)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Classical transplantation (gr. I)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Anatomical transplantation (gr. II)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 1510000

Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg body weight in 10 minutes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg body weight in 10 minutes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 1 minute)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 90
Study: 6355010

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 30711961

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Minicholecystectomy (MC)
Number of subjects: 114
Study: 29776916

Group type: EXPERIMENTAL
Intervention: NIR light therapy (940 nm) to acupoints in the legs and feet, 12 sessions during hemodialysis three times a week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NIR light therapy (940 nm) to acupoints in the legs and feet
Number of subjects: 60
Study: 26462038

Group type: EXPERIMENTAL
Intervention: Crossed pin configuration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral pin configuration
Number of subjects: 60
Study: 25640007

Group type: EXPERIMENTAL
Intervention: 250 mg/day SCSE for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24285458

Group type: EXPERIMENTAL
Intervention: Specialized physiotherapy methods (6 additional massage treatments, 30 minutes each, over a few days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment and basic physiotherapy)
Number of subjects: 30
Study: 21034249

Group type: EXPERIMENTAL
Intervention: Phage treatment (3×10^9 plaque forming units) administered via oral gavage at 24 and 48 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no phage treatment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Phage treatment
Number of subjects: 48
Study: 18298241

Group type: EXPERIMENTAL
Intervention: Live interactive group-specific normative feedback intervention
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 1162
Study: 16572330

Group type: EXPERIMENTAL
Intervention: 1.0% water-soluble reduced chitosan (5.0 g/l)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.1% chlorhexidine solution
Number of subjects: 12
Study: 12573306

Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (EV) 2 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8682988

Group type: EXPERIMENTAL
Intervention: 5 percent potassium nitrate: 0.243 percent sodium fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinically proven, commercially available desensitizing dentifrices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 7515260

Group type: EXPERIMENTAL
Intervention: Aprotinin (10(6) KIU into the pump prime)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Aprotinin (0.5 x 10(6) KIU intravenous bolus after induction and 10(6) KIU into the pump prime)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 79
Study: 2885022

Group type: EXPERIMENTAL
Intervention: Adimolol (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adimolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study: 31278429

Group type: EXPERIMENTAL
Intervention: 755 nm diode laser
Number of subjects: 16

Group type: COMPARATOR
Intervention: 755 nm alexandrite laser
Number of subjects: 16
Study: 28726359

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 63

Group type: COMPARATOR
Intervention: No earplugs (Control)
Number of subjects: 63
Study: 26204987

Group type: EXPERIMENTAL
Intervention: Carraguard microbicide gel
Number of subjects: 5990

Group type: EXPERIMENTAL
Intervention: High adherence (gel used in >=85% of sex acts)
Number of subjects: 5990

Group type: EXPERIMENTAL
Intervention: Coital frequency
Number of subjects: 5990

Group type: EXPERIMENTAL
Intervention: Geographic site (Western Cape vs KZN)
Number of subjects: 5990

Group type: EXPERIMENTAL
Intervention: Contraceptive method
Number of subjects: 5990

Group type: EXPERIMENTAL
Intervention: Partner age difference
Number of subjects: 5990
Study: 25277886

Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC) 65 g dissolved in 500 mL water 30 minutes before lunch
Number of subjects: 45

Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) 60 g dissolved in 500 mL water 30 minutes before lunch
Number of subjects: 45
Study: 23968966

Group type: EXPERIMENTAL
Intervention: Early recovery after surgery
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conservative regimen
Number of subjects: 101
Study: 22052331

Group type: EXPERIMENTAL
Intervention: Wright et al./Case (Group I): (4 × Body wt (BW) (kg)) +7
Number of subjects: 99

Group type: COMPARATOR
Intervention: Shukla et al./Control (Group II): (3 × BW (kg)) +9
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Wright's formula (Group I)
Number of subjects: 99
Study: 20427390

Group type: EXPERIMENTAL
Intervention: LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Number of subjects: 432

Group type: COMPARATOR
Intervention: CAL: clarithromycin (500 mg twice a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: LAL as second-line treatment
Number of subjects: 432

Group type: COMPARATOR
Intervention: CAL as second-line treatment
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: CAL followed by LAL
Number of subjects: 432

Group type: COMPARATOR
Intervention: LAL followed by CAL
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: LAL group with levofloxacin resistance
Number of subjects: 432
Study: 17493978

Group type: EXPERIMENTAL
Intervention: Lightweight 0.4 ounce explorer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Heavier 1.0 ounce explorer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 48
Study: 16170941

Group type: EXPERIMENTAL
Intervention: Blind participants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sighted participants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Drivers responding to pedestrians with mobility devices
Number of subjects: 12

Group type: COMPARATOR
Intervention: Drivers responding to pedestrians without mobility devices
Number of subjects: 12
Study: 12106622

Group type: EXPERIMENTAL
Intervention: Anticoagulation service in managed care organization
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual provider-based care (Control)
Number of subjects: 262
Study: 10072016

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 200
Study: 8616125

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both MgSO4 and phenytoin
Number of subjects: 24
Study: 1581266

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 18
Study: 3878717

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study: 30877053

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 215
Study: 29752179

Group type: EXPERIMENTAL
Intervention: Lovaza (1.86 g of EPA and 1.5 g of DHA daily)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (no Lovaza)
Number of subjects: 291
Study: 26051846

Group type: COMPARATOR
Intervention: Ultrasound (n=32)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Phonophoresis with dexketoprofen (50 mg/session) (n=33)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexketoprofen (50 mg/session) (n=34)
Number of subjects: 99
Study: 25324251

Group type: EXPERIMENTAL
Intervention: Normoxemic management (PaO2=100‐150 mm Hg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hyperoxemic management (PaO2=200‐300 mm Hg)
Number of subjects: 22
Study: 22554205

Group type: EXPERIMENTAL
Intervention: Glycerin 1% formulated with PLL-g-PEG
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systane Lubricant Eye Drops
Number of subjects: 16
Study: 20404743

Group type: EXPERIMENTAL
Intervention: Bedtime dosing of candesartan (with or without diuretic)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Awakening dosing of candesartan (with or without diuretic)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Bedtime dosing of candesartan in morning hypertension group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Awakening dosing of candesartan in morning hypertension group
Number of subjects: 450
Study: 17660024

Group type: EXPERIMENTAL
Intervention: Automatic intra‐aortic balloon pump‐induced pulsatile perfusion during cardiopulmonary bypass (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion during cardiopulmonary bypass (group A)
Number of subjects: 100
Study: 16080364

Group type: EXPERIMENTAL
Intervention: Enterococcus faecium (EF) M‐74 strain with 50 microg of organically bound selenium (E‐group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P-group)
Number of subjects: 0
Study: 12394700

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 2 weeks before surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10188901

Group type: EXPERIMENTAL
Intervention: D1 resection (removal of regional perigastric nodes)
Number of subjects: 400

Group type: COMPARATOR
Intervention: D2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: D1 resection
Number of subjects: 400

Group type: COMPARATOR
Intervention: D2 resection
Number of subjects: 400
Study: 7741862

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (mammography)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Control cancers diagnosed before screening
Number of subjects: 738
Study: 1538350

Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Flexibility training
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 6693294

Group type: EXPERIMENTAL
Intervention: Six meals a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Three meals a day
Number of subjects: 10
Study: 31497674

Group type: EXPERIMENTAL
Intervention: Web-based decision support tools
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard educational materials
Number of subjects: 300
Study: 30577757

Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (TOF 1-2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (TOF 0, PTC 1-5)
Number of subjects: 60
Study: 27104933

Group type: EXPERIMENTAL
Intervention: Everolimus combined with cyclosporine A (CsA) and steroids
Number of subjects: 190

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study: 24725237

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir, dasabuvir, and ribavirin for 12 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir, dasabuvir, and ribavirin for 24 weeks
Number of subjects: 380

Group type: COMPARATOR
Intervention: Historical control (telaprevir-based regimen)
Number of subjects: 380
Study: 22277989

Group type: COMPARATOR
Intervention: MDMA (125 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20066397

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reamed intramedullary nailing
Number of subjects: 0
Study: 17299100

Group type: EXPERIMENTAL
Intervention: Multimodal treatment program including cognitive behavioral therapy, interpersonal therapy, nutritional counseling, and supervised walking exercise (15 sessions).
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (obese individuals without eating disorder).
Number of subjects: 96
Study: 15805342

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 and 4 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo patch and gum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (patch, gum, placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy with cognitive-behavioral therapy
Number of subjects: 120
Study: 12379050

Group type: EXPERIMENTAL
Intervention: Group discussion about second-hand consequences of alcohol use
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (completed the questionnaire only)
Number of subjects: 184
Study: 9927145

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b for 12 months
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b for 6 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Interferon alpha-2b with detectable HCV-RNA after 1 month
Number of subjects: 130
Study: 7775717

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 2324655

Group type: EXPERIMENTAL
Intervention: Rotational manipulation of the cervical spine (n = 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oscillatory mobilization of the cervical spine (n = 4)
Number of subjects: 9
Study: 77413

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study: 30777645

Group type: EXPERIMENTAL
Intervention: Intervention (We Immunize Program with practical strategies training and monthly telephonic expert feedback)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (standard immunization update training only)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intervention (We Immunize Program)
Number of subjects: 62
Study: 26467301

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing brush-on gel (0.2% chlorhexidine digluconate) used once daily for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 38
Study: 25899736

Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted TAP block with bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic‐assisted TAP block with saline
Number of subjects: 80
Study: 24139773

Group type: EXPERIMENTAL
Intervention: 6-month tailored physical activity intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: wellness contact control
Number of subjects: 266
Study: 21130060

Group type: EXPERIMENTAL
Intervention: Biofeedback group (BF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 20
Study: 19245697

Group type: EXPERIMENTAL
Intervention: Individualised home exercise program established and progressed during ten home visits from a physiotherapist, with participants exercising at home up to 6 times per week for 12 months.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Individualised home exercise program
Number of subjects: 350
Study: 16778332

Group type: EXPERIMENTAL
Intervention: Imidapril 2.5 mg once daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 30
Study: 14759425

Group type: EXPERIMENTAL
Intervention: Intravenous methylene blue (1.5 mg/Kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study: 11718638

Group type: EXPERIMENTAL
Intervention: Corticosteroid infiltration
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (NTG) patch (5 mg for 3 days)
Number of subjects: 48
Study: 9399217

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg t.i.d.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg t.i.d.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7584278

Group type: EXPERIMENTAL
Intervention: Recall of distinctive facial feature associated with a name when the occupation is also recalled.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recall of occupation associated with a name.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effects of biographical cues on recall of facial information.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval of facial information and name with biographical details.
Number of subjects: 0
Study: 2824708

Group type: EXPERIMENTAL
Intervention: Late intensification chemotherapy (high-dose chemotherapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 101
Study: 31929199

Group type: EXPERIMENTAL
Intervention: Group Enamic (GE) - Polymer‐Infiltrated Ceramic Network (PICN) CAD/CAM endocrowns
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group CEREC (GC) - feldspathic ceramic CAD/CAM endocrowns
Number of subjects: 20
Study: 30006361

Group type: EXPERIMENTAL
Intervention: 40 mg of the β‐blocker propranolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg of amisulpride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26541307

Group type: EXPERIMENTAL
Intervention: Cogmed working memory training (standard-length or shortened-length)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 136
Study: 26179814

Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy interventions
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (control)
Number of subjects: 1094
Study: 23752285

Group type: EXPERIMENTAL
Intervention: Course on health and prevention of musculoskeletal injuries; Duration: 1 year; Evaluation: 3 questionnaires (beginning, 6 months, 12 months)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no course); Evaluation: 2 questionnaires (beginning, 1 year later)
Number of subjects: 146
Study: 21040376

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Air
Number of subjects: 9
Study: 18945688

Group type: EXPERIMENTAL
Intervention: High testosterone levels
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: High estradiol levels
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: High testosterone:17beta‐diol‐glucuronide ratio
Number of subjects: 1417
Study: 16160693

Group type: EXPERIMENTAL
Intervention: Chemotherapy (beneficial effect group, n = 245)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Chemotherapy (progressive disease group, n = 58)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with 0-1 adverse events)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with 2-5 adverse events)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with >=6 adverse events)
Number of subjects: 303
Study: 12831816

Group type: EXPERIMENTAL
Intervention: Intervention group (n=199) with lifestyle modification and pharmacological treatments individualized by a geriatrician
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (n=201) receiving usual care
Number of subjects: 400
Study: 10928439

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no nimodipine)
Number of subjects: 20
Study: 8880109

Group type: EXPERIMENTAL
Intervention: Ultrasonically-nebulized distilled water (UNDW) - 10 min inhalation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) - stepwise inhalation of 4.5% saline for 0.5, 1, 2, 4, and 8 min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both challenges (HS and UNDW)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between HS and UNDW
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acceptability of HS vs UNDW
Number of subjects: 36
Study: 1847408

Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI) clinical simulation series
Number of subjects: 64
Study: 6089858

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 31100611

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions for 12 weeks)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg for 8 weeks)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sham for group D
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sham for group B
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions for 4 weeks)
Number of subjects: 170